Vibrio cholerae infection, novel drug targets and phage therapy

Future Microbiology

Volumn 6, Issue 10, 2011, Pages 1199-1208

  Fazil, Mobashar Hussain Urf Turabe ^a   Singh, Durg V ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

antibiotic resistance; biofilm; drug target; quorum sensing; V. cholerae; vaccine

Indexed keywords

AMPICILLIN; AZITHROMYCIN; CHLORAMPHENICOL; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CIPROFLOXACIN; COTRIMOXAZOLE; DOXYCYCLINE; FURAZOLIDONE; KANAMYCIN; NALIDIXIC ACID; NEOMYCIN; STREPTOMYCIN; SULFAMETHOXAZOLE; TETRACYCLINE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIOPHAGE; CHOLERA; CLINICAL FEATURE; DIARRHEA; DRUG TARGETING; EPIDEMIC; GENOTYPE; HUMAN; IMMUNITY; NONHUMAN; PRIORITY JOURNAL; QUORUM SENSING; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VIBRIO CHOLERAE;

ANTI-BACTERIAL AGENTS; BACTERIOPHAGES; CHOLERA; CHOLERA TOXIN; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; HUMANS; QUORUM SENSING; VIBRIO CHOLERAE;

BACTERIA (MICROORGANISMS); VIBRIO CHOLERAE;

EID: 80054812792     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.93     Document Type: Review

References (79)

1. Nusrin S, Khan GY, Bhuiyan NA, et al. Diverse CTX phages among toxigenic Vibrio cholerae O1 and O139 strains isolated between 1994 and 2002 in an area where cholera is endemic in Bangladesh. J. Clin. Microbiol. 42, 5854-5856 (2004 (Pubitemid 39664378)
2. Burrus V, Marrero J, Waldor MK. The current ICE age: biology and evolution of SXT-related integrating conjugative elements. Plasmid 55, 173-183 (2006
3. Sack DA, Tacket CO, Cohen MB, et al. Validation of a volunteer model of cholera with frozen bacteria as the challenge. Infect. Immun. 66, 1968-1972 (1998 (Pubitemid 28194090)
4. Watnick PI, Lauriano CM, Klose KE, Croal L, Kolter R. The absence of a flagellum leads to altered colony morphology, biofilm development and virulence in Vibrio cholerae O139. Mol. Microbiol. 39, 223-235 (2001 (Pubitemid 32113497)
5. Olivier V, Salzman NH, Satchell KJ. Prolonged colonization of mice by Vibrio cholerae El Tor O1 depends on accessory toxins. Infect. Immun. 75, 5043-5051 (2007 (Pubitemid 47502178)
6. Kaper JB, Morris JG Jr, Levine MM. Cholera. Clin. Microbiol. Rev. 8, 48-86 (1995
7. Morris JG Jr, Black RE. Cholera and other vibrios in the United States. N. Engl. J. Med. 312, 343-350 (1985 (Pubitemid 15152648)
8. Swerdlow DL, Ries AA. Cholera in the Americas. Guidelines for the clinician. J. Am. Med. Assoc. 267, 1495-1499 (1992
9. Khan WA, Saha D, Rahman A, Salam MA, Bogaerts J, Bennish ML. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomized, double-blind trial. Lancet 360, 1722-1727 (2002 (Pubitemid 35447901)
10. Levine MM, Tacket CO. Recombinant live cholera vaccines. In: Vibrio cholerae and Cholera: Molecular to Global Perspectives. Wachsmuth IK, Blake PA, Olsvik O (Eds). American Society for Microbiology, Washington, DC, USA 39-415 (1994
11. Levine MM, Nalin DR, Craig JP, et al. Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity. Trans. R. Soc. Trop. Med. Hyg. 73, 3-9 (1979 (Pubitemid 9097253)
12. Mosley WH, Aziz KM, Rahman AS, et al. Field trials of monovalent Ogawa and lnaba cholera vaccines in rural Bangladesh-three years of observation. Bull. World Health Org. 49, 381-387 (1973
13. Holmgren J, Clemens J, Sack DA, Svennerholm AM. New cholera vaccines. Vaccine 7, 94-96 (1989 (Pubitemid 19089660)
14. Sur D, Nair GB, Lopez AL, et al. Oral cholera vaccines - call for action. Indian J. Med. Res. 131, 1-3 (2010
15. Ortigao-de-Sampaio MB , Shattock RJ, Hayes P, et al. Increase in plasma viral load after oral cholera immunization of HIV-infected subjects. AIDS 12, F145-F150 (1998 (Pubitemid 28454435)
16. The WHO. WHO Vaccine Trial Registry, 1-16 (2000
17. Calain P, Chaine JP, Johnson E, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? Vaccine 22, 2444-2451 (2004 (Pubitemid 38757343)
18. Faruque SM, Albert MJ, Mekalanos JJ. Epidemiology, genetics, and ecology of toxigenic Vibrio cholerae. Microbiol. Mol. Biol. Rev. 62, 1301-1314 (1998 (Pubitemid 28558300)
19. Pourshafic MR, Grimont F, Saifi M, Grimont PAD. Molecular epidemiological study of Vibrio cholerae from infected patients in Tehran, Iran. J. Med. Microbiol. 49, 1085-1090 (2000
20. Jesudasan MV, Saaya R. Resistance of Vibrio cholerae O1 to nalidixic acid. Indian J. Med. Res. 105, 153-154 (1997 (Pubitemid 27198872)
21. Bhattacharya K, Kanunago S, Sur D, et al. Tetracycline-resistant Vibrio cholerae O1, Kolkata, India. Emerg. Infect. Dis. 17, 568-569 (2011
22. Mitra R, Basu A, Dutta D, Nair GB, Takeda Y. Resurgence of Vibrio cholerae O139 Bengal with altered antibiogram in Calcutta, India. Lancet 348, 1181 (1996 (Pubitemid 26358634)
23. Sabeena F, Thirivikramji G, Radhakutty G, Indu P, Singh DV. In vitro susceptibility of Vibrio cholerae O1 biotype El Tor strains associated with an outbreak of cholera in Kerala, Southern India. J. Antimicrob. Chemother. 47, 361-362 (2001 (Pubitemid 32229584)
24. Das S, Saha R, Kaur IR. Trend of antibiotic resistance of Vibrio cholerae strains from East Delhi. Indian J. Med. Res. 127, 478-482 (2008
25. Yamamoto T, Nair GB, Albert MJ, Parodi C, Takeda Y. In vitro susceptibility of Vibrio cholerae O1 and O139 to antimicrobial agents and appearance of drug resistance plasmids in Vibrio cholerae. Presented at: The Proceeding of the 30th Joint Conference US-Japan Cooperative Medical Science Program for Cholera and Related Diarrheal Diseases Panel. Fukuara, Japan 1994.
26. Waldor MK, Tschape H, Mekalanos JJ. A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139. J. Bacteriol. 178, 4157-4165 (1996 (Pubitemid 26240897)
27. Amita M, Choudhury SR, Thungapathra M, Ramamurthy T, Nair GB, Ghosh A. Class 1 integrons and SXT elements in El Tor strains isolated before, and after 1992 Vibrio cholerae outbreak, Calcutta, India. Emerg. Infect. Dis. 9, 500-502 (2003 (Pubitemid 37070422)
28. Dalsgaard A, Forslund A, Sandvang D, Arntzen L, Keddy K. Vibrio cholerae O1 outbreak isolates in Mozambique and South Africa in 1998 are multiple drug resistant, contain the SXT element and the aadA2 gene located on class 1 integrons. J. Antimicrob. Chemother. 48, 827-838 (2001 (Pubitemid 33735319)
29. Sinha S, Chakraborty R, De K, et al. Escalating association of Vibrio cholerae O139 with cholera outbreaks in India. J. Clin. Microbiol. 40, 2635-2637 (2002 (Pubitemid 34747378)
30. Yam W, Yuen K, Wong S, Que T. Vibrio cholerae O139 susceptible to vibriostatic agent O/129 and co-trimoxazole. Lancet 344, 404-405 (1994 (Pubitemid 24248217)
31. Falbo V, Carattoli A, Tosini F, Pezzella C, Dionisi AM, Luzzi I. Antibiotic resistance conferred by a conjugative plasmid and a Class I integron in Vibrio cholerae O1 El Tor strains isolated in Albania and Italy. Antimicrob. Agents Chemother. 43, 693-696 (1999 (Pubitemid 29109544)
32. Dalsgaard A, Forslund A, Serichantalergs O, Sandvang D. Distribution and content of Class 1 integrons in different Vibrio cholerae O-serotype strains isolated in Thailand. Antimicrob. Agents Chemother. 44, 1315-1321 (2000 (Pubitemid 30228311)
33. Faruque SM, Sack DA, Sack RB, Colwell RR, Takeda Y, Nair GB. Emergence and evolution of Vibrio cholerae O139. Proc. Natl Acad. Sci. USA 100, 1304-1309 (2003 (Pubitemid 36183997)
34. Mazel D. Integrons: agents of bacterial evolution. Nat. Rev. Microbiol. 4, 608-620 (2006 (Pubitemid 44317023)
35. Pan JC, Ye R, Wang HQ, et al. Vibrio cholerae O139 multiple drug resistance mediated by Yersinia pestis pIP1202-like conjugative plasmids. Antimicrob. Agents Chemother. 52, 3829-3836 (2008
36. Beaber JW, Hochhut B, Waldor MK. SOS response promotes horizontal dissemination of antibiotic resistance genes. Nature 427, 72-74 (2004 (Pubitemid 38094823)
37. Lindenbaum J, Greenough WB, Islam MR. Antibiotic therapy of cholera. Bull World Health Organ. 36, 871-883 (1967
38. Chakrabarti MK, Bhattacharya MK, Bhattacharya J, Bhattacharya SK, Mahalanabis D. Evaluation of different antibiotics in inhibiting colonization of Vibrio cholerae O1 and O139 in the rabbit intestine. Chemotherapy 44, 108-111 (1998 (Pubitemid 28105423)
39. Ramamurthy T. Antibiotic resistance in Vibrio cholerae. In: Vibrio cholerae: Genomics and Molecular Biology. Faruque SM, Nair GB (Eds). Caister Academic Press, London, UK, 191-207 (2008
40. Kummerer K. Antibiotics in the aquatic environment - a review. Chemosphere 75, 417-434 (2009
41. Khan WA, Bennish ML, Seas C, et al. Randomised controlled comparison of single-dose ciprofloxacin and doxycycline for cholera caused by Vibrio cholerae O1 or O139. Lancet 348, 296-300 (1996 (Pubitemid 26254629)
42. Goldstein F, Gerbaud G, Courvalin P. Transposable resistance to trimethoprim and O/129 in Vibrio cholerae. J. Antimicrob. Chemother. 17, 559-569 (1986 (Pubitemid 16114799)
43. Van Dellen KL, Watnick PI. The Vibrio cholera biofilm: a target for novel therapies to prevent and treat cholera. Drug Discov. Today Dis. Mech. 3, 261-266 (2006 (Pubitemid 44356312)
44. Zhu J, Miller MB, Vance RE, Dziejman M, Bassler BL, Mekalanos JJ. Quorum-sensing regulators control virulence gene expression in Vibrio cholerae. Proc. Natl Acad. Sci. USA 99, 3129-3134 (2002 (Pubitemid 34240597)
45. Hammer BK, Bassler BL. Quorum sensing controls biofilm formation in Vibrio cholerae. Mol. Microbiol. 50, 101-104 (2003
46. Miller MB, Skorupski K, Lenz DH, Taylor RK, Bassler BL. Parallel quorum sensing systems converge to regulate virulence in Vibrio cholerae. Cell 110, 303-314 (2002
47. Chen X, Schauder S, Potier N, et al. Structural identification of a bacterial quorum-sensing signal containing boron. Nature 415, 545-549 (2002 (Pubitemid 34130611)
48. Lenz DH, Miller MB, Zhu J, Kulkarni RV, Bassler BL. CsrA and three redundant small RNAs regulate quroum sensing in Vibrio cholerae. Mol. Mirobial. 58, 1186-1202 (2007
49. Waters CM, Lu W, Rabinowitz JD, et al. Quorum sensing controls biofilm formation in Vibrio cholerae through modulation of cyclic Di-GMP. J. Bacteriol. 190, 2527-2536 (2008 (Pubitemid 351466348)
50. Huq A, Whitehouse CA, Grim CJ, et al. Biofilms in water, its role and impact in human disease transmission. Curr. Opin. Biotechnol. 19, 244-247 (2008
51. Faruque SM, Biswas K, Udden SM, et al. Transmissibility of cholera: in vivo-formed biofilms and their relationship to infectivity and persistence in the environment. Proc. Natl Acad. Sci. USA. 103, 6350-6355 (2006
52. Rasko DA, Moreira CG, Li de R, et al. Targeting QseC signaling and virulence for antibiotic development. Science 321, 1078-1080 (2008
53. Swem LR, Swem DL, OLoughlin CT, et al. A quorum-sensing antagonist targets both membrane-bound and cytoplasmic receptors and controls bacterial pathogenicity. Mol. Cell 35, 143-153 (2009)
54. Wang W, Morohoshi T, Ikeda T, et al. Inhibition of Lux quorum-sensing system by synthetic N-acyl-l-homoserine lactone analogues. Acta. Biochim. Biophys. Sin. (Shanghai). 40, 1023-1028 (2008)
55. Brackman G, Celen S, Baruah K, et al. AI-2 quorum-sensing inhibitors affect the starvation response and reduce virulence in several Vibrio species, most likely by interfering with LuxPQ. Microbiology 155, 4114-4122 (2009)
56. Alfaro JF, Zhang T, Wynn DP, et al. Synthesis of LuxS inhibitors targeting bacterial cell-cell communication. Org. Lett. 6, 3043-3046 (2004 (Pubitemid 39233115)
57. De Silva RS, Kovacikova G, Lin W, et al. Crystal structure of the Vibrio cholerae quorum-sensing regulatory protein HapR. J. Bacteriol. 189, 5683-5691 (2007 (Pubitemid 47206415)
58. Defoirdt T, Miyamoto CM, Wood TK, et al. The natural furanone (5Z)-4-bromo-5- (bromomethylene)-3-butyl-2(5H)-furanone disrupts quorum sensing-regulated gene expression in Vibrio harveyi by decreasing the DNA-binding activity of the transcriptional regulator protein luxR. Environ. Microbiol. 9, 2486-2495 (2007 (Pubitemid 47366661)
59. Brackman G, Defoirdt T, Miyamoto C, et al. Cinnamaldehyde and cinnamaldehyde derivatives reduce virulence in Vibrio spp. by decreasing the DNA-binding activity of the quorum sensing response regulator LuxR. BMC Microbiol. 8, 149 (2008
60. Jertborn M, Svennerholm AM, Holmgren J. Immunological memory after immunization with oral cholera B subunit - whole-cell vaccine in Swedish volunteers. Vaccine 12, 1078-1082 (1994
61. Jertborn M, Nordstrom I, Kilander A, Czerkinsky C, Holmgren J. Local and systemic immune responses to rectal administration of recombinant cholera toxin B subunit in humans. Infect. Immun. 69, 4125-4128 (2001 (Pubitemid 32496267)
62. Olsvik O, Wahlberg J, Petterson B, et al. Use of automated sequencing of polymerase chain reaction-generated amplicons to identify three types of cholera toxin subunit B in Vibrio cholerae O1 strains. J. Clin. Microbiol. 31, 22-25 (1993 (Pubitemid 23006572)
63. Bhuiyan NA, Nusrin S, Alam M, et al. Changing genotypes of cholera toxin (CT) of Vibrio cholerae O139 in Bangladesh and description of three new CT genotypes. FEMS Immunol. Med. Microbiol. 57, 136-141 (2009
64. Tamplin ML, Ahmed MK, Jalali R, Colwell RR. Variation in epitopes of the B subunit of El Tor and classical biotype Vibrio cholerae O1 cholera toxin. J. Gen. Microbiol. 135, 1195-1200 (1989 (Pubitemid 19135401)
65. Jobling MG, Holmes RK. Mutational analysis of ganglioside GM(1)-binding ability, pentamer formation, and epitopes of cholera toxin B (CTB) subunits and CTB/heat-labile enterotoxin B subunit chimeras. Infect. Immun. 70, 1260-1271 (2002 (Pubitemid 34163400)
66. Aman AT, Fraser S, Merritt EA, et al. A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity. Proc. Natl Acad. Sci. USA 98, 8536-8541 (2001 (Pubitemid 32678063)
67. Fazil MHUT, Kumar S, Farmer R, Pandey HP, Singh DV. Binding efficiencies of carbohydrate ligands with different genotypes of cholera toxin B: molecular modelling, dynamics and docking simulation studies. J. Mol. Model. doi: 10.1007/s00894-010- 0947-6Online First™ (2011) (Epub ahead of print
68. Cavasotto CN, Phatak SS. Homology modeling in drug discovery: current trends and applications. Drug Discov. Today 14, 676-683 (2009
69. Thiagarajah JR, Verkman AS. New drug targets for cholera therapy. Trends Pharmacol. Sci. 26, 172-175 (2005 (Pubitemid 40432650)
70. Yamaichi Y, Duigou S, Shakhnovich EA, Waldor MK. Targeting the replication initiator of the second Vibrio chromosome: towards generation of Vibrionaceae-specific antimicrobial agents. PLoS Pathog. 5, e1000663 (2009
71. Hung DT, Shakhnovich EA, Pierson E, Mekalanos JJ. Small-molecule inhibitor of Vibrio cholerae virulence and intestinal colonization. Science 310, 670-674 (2005 (Pubitemid 41528158)
72. Bax BD, Chan PF, Eggleston DS, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 466, 935-940 (2010
73. Grover PA, Kuntal H, Sharma V. In silico prediction of drug targets in Vibrio cholerae. Protoplasma doi: 10.1007/s00709-010- 0255-0 (2010) (Epub ahead of print
74. Summers W. Bacteriophage therapy. Ann. Rev. Microbiol. 55, 437-451 (2001 (Pubitemid 32978113)
75. Marcuk LM, Nikiforov VN, Scerbak JF, et al. Clinical studies of the use of bacteriophage in the treatment of cholera. Bull. World Health. Organ. 45, 77-83 (1971
76. WHO. Cholera factsheet No. 107 www.who.int/mediacentre/factsheets/fs107/ en/index.html
77. WHO. Prevention and control of cholera outbreaks: WHO policy and recommendations www.emro.who.int/csr/Media/PDF/cholera-whopolicy.pdf
78. WHO. Initiative for Vaccine Research (IVR) www.who.int/vaccine-research/ diseases/diarrhoeal/en/index3.html
79. The genomic target database http://iioab-dgd.webs.com/vcholeraepumd.htm